Bimini Biotech

BIMINI Biotech is a Netherlands-based startup that operates in the biotechnology industry, specifically focusing on the development of novel therapeutics for hematological cancers, such as lymphomas and leukemias. The company's approach is based on proprietary technology that targets the Wiskott-Aldrich-Syndrome Protein (WASp), a protein that is only found in blood cells. Modulating this protein has shown to have a strong anti-cancer effect.

BIMINI Biotech's business model revolves around the development and commercialization of its proprietary portfolio of products, including BM-011, a WASp activator, and BM-013, a WASp inhibitor. These products have shown promising results in treating difficult-to-treat non-Hodgkin lymphomas and leukemias, respectively. The company's clients are primarily healthcare providers and patients suffering from these types of cancers.

The company generates revenue through the sale of its products and through grants and investments. For instance, BIMINI Biotech has received a MIT feasibility grant of €20,000 for the AUTO-WASP project, and an additional investment of €250,000 from lead investor Libertatis Ergo.

The team at BIMINI Biotech is a mix of young ambitious entrepreneurs, scientific key-opinion-leaders, and seasoned business experts, which positions the company well for future growth and innovation in the biotech industry.

Keywords: Biotechnology, Hematological Cancers, WASp Protein, Anti-Cancer, Therapeutics, Lymphomas, Leukemias, Healthcare Providers, Grants and Investments, Innovation.